This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
The Freely Filtered team (minus Samira) spent an hour doing a deep dive on the Risk Score for IgA nephropathy and how many grams of IgA a human makes everyday.
Listen
Subscribe
Leave a review on iTunes.
NSMC Intern Daniyal Jafree stepped up to write an excellent tweetorial on the latest NephJC discussion. Take a look.
Welcome to the @NSMCInternship #tweetorial for this week’s study on a new risk prediction tool for IgA nephropathy, appearing in @JAMAInternalMed. Check out these unhappy glomeruli with mesangial IgA deposits in green from https://t.co/5t2NImFGj4 (1/16) pic.twitter.com/nDEkuxduK6
— Nephrology Jrnl Club (@NephJC) June 3, 2019
